Accueil / Communiqués / Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar

Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar

Monday, January 14th 2019 at 1:08pm UTC

GUANGZHOU, China–(BUSINESS WIRE)– Bio-Thera Solutions Ltd (“Bio-Thera”) announced today that it has
reached a licensing agreement with Cipla Limited (BSE: 500087; NSE:
CIPLA EQ; and hereafter referred to as “Cipla”) for BAT1706, its
bevacizumab biosimilar, under which Cipla will have exclusive rights to
distribute and market the drug in select emerging markets.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190114005291/en/

BAT-1706 is a mAb biosimilar to Genentech’s Avastin® which is
currently approved for six indications including metastatic colorectal
cancer, recurrent glioblastoma and non-squamous non-small cell lung
cancer. Bio-Thera’s BAT-1706 is currently in a global Phase III study (NCT03329911)
in patients with previously untreated advanced non-squamous non-small
cell lung cancer. Bio-Thera intends to file for regulatory approval with
the China National Medical Products Administration (NMPA), the European
Medicines Agency (EMA) and the United States Food and Drug
Administration (USFDA) in 2020.

This partnership will leverage Cipla’s strong local presence, sales and
marketing capabilities in the select emerging markets. Bio-Thera will be
responsible for full development, product registration with the FDA and
EMA, and commercial supply of BAT1706 out of its manufacturing
facilities in Guangzhou, China.

“Bio-Thera is pleased to partner with Cipla to commercialize our lead
biosimilar program in select emerging markets”, said Dr. Shengfeng Li,
CEO of Bio-Thera. “This partnership is an important first step towards
making BAT1706, our bevacizumab biosimilar product, availability
globally to help increase patient access to this important cancer
therapeutic at affordable prices.”

“This agreement is in keeping with Cipla’s stated intention to build a
strong pipeline of biosimilars through partnerships. We are committed to
working towards ensuring patients receive access to life-saving drugs.
Through this partnership, Cipla will leverage its strengths in marketing
to take this key oncology biosimilar to patients in need.” said Umang
Vohra, MD & Global CEO of Cipla Limited.

About Bio-Thera Solutions

Bio-Thera Solutions Ltd, a leading global biotechnology company in
Guangzhou, China, is dedicated to researching and developing novel
therapeutics for the treatment of cancer, autoimmune, cardiovascular
diseases, and other serious unmet medical needs, as well as biosimilars
for existing, branded biologics to treat a range of cancer and
autoimmune diseases. A leader in next generation antibody discovery and
engineering, the company has advanced five candidates into late stage
clinical trials and has applied for marketing authorization for one
candidate. In addition, the company has multiple promising candidates in
early clinical trials and IND-enabling studies, focusing on innovative
targets in immuno-oncology and autoimmune diseases. For more
information, please visit www.bio-thera.com/en/
or follow us on Twitter (@bio_thera_sol)
and wechat (Bio-Thera).

About Cipla Limited:

Established in 1935, Cipla is a global pharmaceutical company focused on
agile and sustainable growth, complex generics, and deepening portfolio
in our home markets of India, South Africa, North America, and key
regulated and emerging markets. Our strengths in the respiratory,
anti-retroviral, urology, cardiology and CNS segments are well-known.
Our 44 manufacturing sites around the world produce 50+ dosage forms and
1,500+ products using cutting-edge technology platforms to cater to our
80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT
Sept’18), 3rd largest in the pharma private market in South Africa
(IQVIA YTD Aug’18), and is among the most dispensed generic players in
the US. For over eight decades, making a difference to patients has
inspired every aspect of Cipla’s work. Our paradigm-changing offer of a
triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day
in Africa in 2001 is widely acknowledged as having contributed to
bringing inclusiveness, accessibility and affordability to the centre of
the movement. A responsible corporate citizen, Cipla’s humanitarian
approach to healthcare in pursuit of its purpose of ‘Caring for Life’
and deep-rooted community links wherever it is present make it a partner
of choice to global health bodies, peers and all stakeholders. For more,
please visit www.cipla.com,
or click on TwitterFacebookLinkedIn.

Contacts

Bio-Thera Solutions Ltd
Bert E. Thomas IV
Email: bethomas@bio-thera.com

Cipla Limited
Corporate Communications
Heena
Kanal
E-Mail: CorpComm@cipla.com

Investor Relations
Naveen Bansal
E-Mail: Investor.Relations@cipla.com

Source: Bio-Thera Solutions Ltd


Voir aussi

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Friday, January 18th 2019 at 9:05pm UTC WALTHAM, Mass.–(BUSINESS WIRE)– Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today …